Zydus Cadila has received the final approval from the United States Food & Drug Administration (USFDA) to market Ziprasidone Hydrochloride Capsules in strengths of 20 mg, 40 mg, 60 mg, and 80 mg. 

Ziprasidone, an antipsychotic medication, is used to treat schizophrenia and the manic symptoms of bipolar disorder (manic depression). The drug will be manufactured at the group's formulations manufacturing facility at the Phanna SEZ, Ahmedabad.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04. 

Shares of the company declined Rs 4.45, or 0.95%, to trade at Rs 463.95. The total volume of shares traded was 157,819 at the BSE (12.16 p.m., Wednesday).